24
Oct
2017

AbbVie Shells Out $205M Upfront for Alector’s Antibodies Vs. Alzheimer’s

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Alector, Staying Private for Now, Pulls in $133M for Alzheimer’s R&D